Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares -February 02, 2024 at 06:40 pm EST

SAN CARLOS, Calif., Feb. 02, 2024 -- Vaxcyte, Inc. , a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases,...

Related Keywords

Charlotte ,North Carolina ,United States ,New York ,Boston ,Massachusetts ,Jennifer Zibuda ,Janet Graesser ,Corporate Communications ,Groupa Strep ,Needham Company ,Leerink Partners ,Exchange Commission ,Vaxcyte Inc ,Syndicate Department ,Equity Syndicate Department ,Nasdaq ,Evercore Group ,Globenewswire Inc ,Prospectus Department ,Sutro Biopharma Inc ,Tryon Street ,Capital Markets ,Sutro Biopharma ,Vice President ,Senior Director ,Markets ,